Highest-materiality recent filing
Progyny Q2 revenue $350.5M (+5.3% YoY), adjusted EBITDA $62.1M; FY revenue guidance $1.36B-$1.385B
Revenue $350.5M, up 5.3% YoY; gross margin 25.5% vs 23.7% prior year.
Progyny shareholders approve elimination of supermajority voting requirements
Super majority amendments passed with >65M votes for, 357K against.
Progyny board approves $200M share repurchase program
Board authorized repurchase of up to $200M of common stock, funded from available cash balances.
Progyny Q1 rev $328.5M (+1.4%), adj EPS $0.50; guides FY rev $1.365-1.405B
Q1 revenue $328.5M (+1.4% YoY); ex-lost client revenue grew 12.2%. Net income $24.2M ($0.29 diluted) vs $15.1M.
Progyny settles derivative suit over director pay; caps annual comp at $288k per director
Derivative action challenged non-employee director compensation since 2020; settlement includes governance reforms.
Progyny Q4 revenue up 6.7% to $318.4M; guides FY2026 revenue $1.355B-$1.405B
Q4 revenue $318.4M (+6.7% YoY); FY2025 revenue $1.2887B (+10% YoY); gross margin expanded to 24.1%.
Progyny expects Q4 2025 revenue, net income, Adj. EBITDA slightly above prior guidance
CEO cites favorable Q4 member engagement vs. November guidance.
Progyny President Michael Sturmer to depart Dec 31, 2025; no successor named
President Michael Sturmer's employment ends Dec 31, 2025.
Progyny Q3 revenue $313.3M (+9.3% YoY), raises FY2025 guidance; board authorizes $200M buyback
Revenue $313.3M (+9.3% YoY), net income $13.9M ($0.15 EPS), adj. EBITDA $55.0M (17.5% margin).
Progyny Q2 revenue $332.9M (+9.5% YoY); raises FY2025 guidance on strong member engagement
Q2 revenue $332.9M, up 9.5% YoY; ex-large-client transition revenue grew 18%.
Progyny enters $200M credit facility; Q2 results expected slightly above guidance
Entered $200M revolving credit facility maturing July 1, 2030; undrawn at closing.
Progyny shareholders reject advisory vote on executive compensation at 2025 annual meeting
Director nominees Norman Payson, Debra Morris, Elizabeth Bierbower elected with majority votes.
Progyny Q1 revenue $324M (+16.5% YoY), raises FY2025 guidance above prior outlook
Q1 revenue $324.0M (+16.5% YoY); gross margin 23.4% vs 22.4% a year ago.
Director Dr. Fred E. Cohen to leave Progyny board after 2025 Annual Meeting
Dr. Cohen notified Progyny on April 9, 2025 of his decision not to stand for reelection at the 2025 Annual Meeting.
Q4 2024 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 EPS); Adj. EBITDA $47.5M (15.9% margin).
Progyny Q4 rev $298.4M (+10.6%); large client non-renewal pressures 2025 guide of 1-5% growth
Q4 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 diluted EPS) vs $13.5M ($0.13) prior year.
Progyny appoints Debra Morris to board effective Jan 16, 2025
Debra Morris appointed as Class III director, term expires at 2025 annual meeting.
Progyny expects Q4 2024 revenue, net income, Adjusted EBITDA slightly above prior guidance
Company updates guidance at JPM Healthcare Conference; Q4 results expected slightly above November ranges.
Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance
Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.
Progyny loses client representing ~12-13% of revenue; termination effective Jan 1, 2025
Client with ~670k members exercised 90-day termination option; no disputes or service issues cited.
Progyny holds inaugural Investor Day; presentation furnished without new financial data
Hosted first-ever Investor Day on August 12, 2024; webcast replay available on website.
Progyny Q2 beats on adjusted EBITDA but cuts full-year guidance on lower revenue per member
Q2 revenue $304.1M (+8.8% YoY), record Adj. EBITDA $54.5M (+15% YoY), margin 17.9%.
Progyny stockholders re-elect directors, ratify EY, approve say-on-pay at 2024 annual meeting
Elected directors Anevski, Holstein, Park, Schlanger with 62M+ votes for each; broker non-votes 5,878,612.
Progyny board authorizes $100M share repurchase program
Board approved a new $100M share repurchase program on May 22, 2024.
Progyny Q1 revenue up 7.6% to $278M; cuts FY revenue guidance to $1.23-1.27B
Q1 revenue $278.1M (+7.6% YoY), net income $16.9M ($0.17 diluted EPS), adjusted EPS $0.39.
Progyny reports record FY23 revenue $1.09B (+38%); guides FY24 $1.285-$1.315B
FY23 revenue $1,088.6M (+38% YoY); net income $62.0M ($0.62 diluted EPS), adj. EBITDA $187.1M (+49%).
Progyny Q3 rev $280.9M (+37% YoY), net income $15.9M; raises FY guidance
Record quarterly revenue $280.9M, up 37% YoY; net income $15.9M ($0.16 diluted EPS).
Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance
Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.
Progyny shareholders reject advisory say-on-pay vote at 2023 annual meeting
Class I directors Lloyd Dean, Kevin Gordon, Cheryl Scott elected with 78.8M, 55.1M, 56.3M votes for, respectively.
Progyny Q1 revenue $258.4M (+50% YoY); raises FY2023 guidance
Net income $17.7M ($0.18 diluted EPS) vs $5.0M ($0.05) in Q1 2022.
Progyny reaffirms strong utilization, 5.4M covered lives, new channel partners
Affirms strong utilization for fertility services across >370 clients, representing ~5.4 million covered lives.
Progyny discloses less than 2% of cash held at SVB, considers exposure immaterial
Less than 2% of cash, cash equivalents, and marketable securities as of Dec 31, 2022 were at risk from SVB receivership.
Progyny Q4 revenue $214.3M (+68% YoY); FY2022 revenue $786.9M (+57%); guides FY2023 above $1B
Q4 2022 revenue $214.3M, up 68% YoY; gross profit $44.5M (+77%); net income $3.4M ($0.03 diluted EPS).
Progyny reaffirms FY2022 high-end guidance; expects record Q4 operating cash flow ~$50M
Q4 and FY2022 revenue, net income, Adj. EBITDA expected at or near high-end of guidance issued Nov 28, 2022.
Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M
Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.
Progyny Q3 revenue $205.4M (+68% YoY); raises FY2022 revenue guidance to $775-785M
Revenue $205.4M (+68% YoY); net income $13.2M ($0.13 EPS) vs $16.8M ($0.17) year ago.
Progyny appoints Lloyd H. Dean to board of directors, expanding board to ten
Board expanded from 9 to 10; Dean appointed as Class I director effective Aug 30, 2022.
Progyny Q2 revenue $195M (+52% YoY); raises FY2022 guidance lower end
Revenue $195M vs $128.7M YoY; net income $8.8M ($0.09 diluted EPS) vs $18.7M ($0.19).
Progyny shareholders elect three Class III directors at 2022 annual meeting
Dr. Fred E. Cohen elected with 54.8M for, 24.0M withheld; broker non-votes 4.9M.
Progyny Q1 revenue $172.2M (+41%); net income $5.0M; raises FY22 guidance lower end
Revenue $172.2M (+41% YoY); gross profit $32.9M (+14%); net income $5.0M ($0.05 EPS) vs $15.2M prior year.
Director Malissia Clinton resigns from Progyny Board effective April 18, 2022
Malissia Clinton resigned from the Board and Nominating and Corporate Governance Committee, effective April 18, 2022.
Progyny reports FY2021 revenue $500.6M (+45% YoY); guides FY2022 rev $730-775M (+50% midpt)
FY2021 revenue $500.6M (45% growth); net income $65.8M ($0.66 EPS); adj. EBITDA $67.3M (13.5% margin, +410bps).
Progyny Reports Q3 2021 Revenue of $122.3M, Appoints Pete Anevski as CEO
Q3 2021 revenue $122.3M (+24% YoY), net income $16.8M vs $4.8M in prior year.
Progyny Q2 revenue surges 99% to $128.7M; net income of $18.7M vs loss a year ago
Q2 net income of $18.7M ($0.19 diluted EPS) vs net loss of $1.1M in Q2 2020
On April 9, 2025, Dr. Fred E. Cohen notified the Board of Directors of Progyny, Inc. (the “Company”) of his decision not to stand for reelection at the Company’s 2025 Annual Meeting of Stockholders.
On January 10, 2025, the board of directors (the “Board”) of Progyny, Inc. (the “Company”) appointed Debra Morris to serve as a Class III director of the Company, effective January 16, 2025.
On August 30, 2022, the board of directors (the " Board ") of Progyny, Inc. (the " Company ") increased the size of its Board from nine (9) to ten (10) directors and appointed Lloyd H. Dean to serve as Class I director of the Company, effective as of such date.
On April 2, 2022, Malissia Clinton notified the board of directors (the “Board”) of Progyny, Inc. (the “Company”) of her resignation from the Board and from the Nominating and Corporate Governance Committee of the Board, in each case effective April 18, 2022.
On November 4, 2021, Progyny, Inc. (the “Company”) announced that David Schlanger plans to transition to the role of Executive Chairman, effective as of January 1, 2022
Beth Seidenberg, M.D., who currently serves as Chair of the Board, will assume the position of Lead Independent Director.
the Board has appointed Mr. Anevski as a director of the Company effective as of the date he becomes Chief Executive Officer.
Michael Sturmer, 45, who currently serves as Executive Vice President, Chief Growth and Strategy Officer, will succeed Mr. Anevski as President, effective as of January 1, 2022.
Pete Anevski, 54, who currently serves as President and Chief Operating Officer, will succeed Mr. Schlanger as Chief Executive Officer, effective as of January 1, 2022.
Max materiality 0.95 · Median 0.75 · Most common event earnings